Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer

被引:63
作者
Bae, Woo Kyun [2 ]
Hwang, Jun Eul [2 ]
Shim, Hyun Jeong [2 ]
Cho, Sang Hee [1 ,2 ]
Lee, Joon Kyoo
Lim, Sang-Chul
Chung, Woong-Ki [2 ]
Chung, Ik-Joo [3 ]
机构
[1] Chonnam Natl Univ, Dept Internal Med, Hwasun Hosp, Hwasun 519809, Hwasun Gun, South Korea
[2] Chonnam Natl Univ, Sch Med, Dept Hematol Oncol, Kwangju 501757, South Korea
[3] Chonnam Natl Univ, Sch Med, Brain Korea Project 21, Ctr Biomed Human Resources, Kwangju 501757, South Korea
关键词
Nasopharyngeal carcinoma; Docetaxel; Induction chemotherapy; Chemoradiotherapy; SQUAMOUS-CELL CARCINOMA; CONCURRENT CHEMORADIOTHERAPY; RANDOMIZED-TRIAL; ASIAN PATIENTS; RADIOTHERAPY; PACLITAXEL; HEAD; NECK; FLUOROURACIL; CARBOPLATIN;
D O I
10.1007/s00280-009-1152-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study sought to determine the feasibility and safety of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (5-FU) triple combination chemotherapy (TPF) followed by concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal cancer (NPC). Patients with advanced NPC were treated with three cycles of induction chemotherapy. Docetaxel (70 mg/m(2)) and cisplatin (75 mg/m(2)) were given on day 1, followed by 5-FU (1,000 mg/m(2)) as a continuous infusion for 4 days. After induction chemotherapy, cisplatin was given at a dose of 100 mg/m(2) every 3 weeks with radiotherapy. Thirty-three patients were enrolled; all patients were stage III (n = 4, 12.1%) or IV (n = 29, 87.9%). Among the patients, 32 patients completed both induction TPF therapy and CCRT, with responses as follows: five patients (15.2%) achieved a complete response (CR), and 27 patients (81.8%) a partial response (PR). At 6 weeks after CCRT, 23 patients (69.7%) had a CR and 9 patients (27.3%) a PR. The 3-year progression-free survival was 75.6% and the 3-year overall survival was 86.1%. Neutropenia (72.7%), febrile neutropenia (9.1%), and nausea (9.1%) were the most severe toxicities (grade 3-4) during induction chemotherapy, and mucositis (39.4%), fatigue (15.2%), and nausea (9.1%) were the most common toxicities (grade 3-4) during CCRT. Although most patients had stage IV NPC, the TPF induction chemotherapy followed by CCRT showed promising activity with manageable toxicity. These results demonstrated the possibility of effective treatment with the aim of not only a palliative, but also a curative, approach to the treatment of advanced NPC.
引用
收藏
页码:589 / 595
页数:7
相关论文
共 27 条
[1]   Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma [J].
Al-Amro, A ;
Al-Rajhi, N ;
Khafaga, Y ;
Memon, M ;
Al-Hebshi, A ;
El-Enbabi, A ;
El-Husseiny, G ;
Radawi, A ;
Belal, A ;
Allam, A ;
El-Sebaie, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (02) :508-513
[2]   Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[3]   UNDIFFERENTIATED NASOPHARYNGEAL CANCER (UCNT) - CURRENT DIAGNOSTIC AND THERAPEUTIC ASPECTS [J].
ALTUN, M ;
FANDI, A ;
DUPUIS, O ;
CVITKOVIC, E ;
KRAJINA, Z ;
ESCHWEGE, F .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (03) :859-877
[4]   Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer [J].
Au, E ;
Tan, EH ;
Ang, PT .
ANNALS OF ONCOLOGY, 1998, 9 (03) :327-329
[5]   Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients [J].
Baujat, B ;
Audry, W ;
Bourhis, J ;
Chan, ATC ;
Onat, H ;
Chua, DTT ;
Kwong, DLW ;
al-Sarraf, M ;
Chi, KH ;
Hareyama, M ;
Leung, SF ;
Thephamongkhol, K ;
Pignon, JP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01) :47-56
[6]   DOCETAXEL (TAXOTERE(R)) - AN ACTIVE-DRUG FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
CATIMEL, G ;
VERWEIJ, J ;
MATTIJSSEN, V ;
HANAUSKE, A ;
PICCART, M ;
WANDERS, J ;
FRANKLIN, H ;
LEBAIL, N ;
CLAVEL, M ;
KAYE, SB .
ANNALS OF ONCOLOGY, 1994, 5 (06) :533-537
[7]   Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: Therapeutic monitoring with plasma Epstein-Barr virus DNA [J].
Chan, ATC ;
Ma, BBY ;
Lo, D ;
Leung, SF ;
Kwan, WH ;
Hui, EP ;
Mok, TSK ;
Kam, M ;
Chan, LS ;
Chiu, SKW ;
Yu, KH ;
Cheung, KY ;
Lai, K ;
Lai, M ;
Mo, F ;
Yeo, W ;
King, A ;
Johnson, PJ ;
Teo, PML ;
Zee, B .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3053-3060
[8]   Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial [J].
Chan, ATC ;
Teo, PML ;
Ngan, RK ;
Leung, TW ;
Lau, WH ;
Zee, B ;
Leung, SF ;
Cheung, FY ;
Yeo, W ;
Yiu, HH ;
Yu, KH ;
Chiu, KW ;
Chan, DT ;
Mok, T ;
Yuen, KT ;
Mo, F ;
Lai, M ;
Kwan, WH ;
Choi, P ;
Johnson, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2038-2044
[9]   Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials [J].
Chua, DTT ;
Ma, J ;
Sham, JST ;
Mai, HQ ;
Choy, DTK ;
Hong, MH ;
Lu, TX ;
Min, HQ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1118-1124
[10]   Locoregionally advanced nasopharyngeal carcinoma:: Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin -: A phase II study [J].
Ferrari, D. ;
Chiesa, F. ;
Codeca, C. ;
Calabrese, L. ;
Jereczek-Fossa, B. A. ;
Alterio, D. ;
Fiore, J. ;
Luciani, A. ;
Floriani, I. ;
Orecchia, R. ;
Foa, P. .
ONCOLOGY, 2008, 74 (3-4) :158-166